New insider activity at Jazz Pharmaceuticals ( (JAZZ) ) has taken place on March 9, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Senior Vice President and Chief Accounting Officer Patricia Carr has sold 2,723 shares of Jazz Pharmaceuticals stock in a recent transaction, with the total value of the sale amounting to $503,645.
Recent Updates on JAZZ stock
Jazz Pharmaceuticals shares reacted to a wave of analyst updates driven by its strong Q4 and full‑year results, plus growing confidence in its pipeline. Firms cited record revenue, durable cash generation, and upside from oncology assets like zanidatamab and ONC206, while also factoring in guidance for slower 2026 growth and rising R&D as Jazz pivots from its legacy sleep franchise toward more diversified epilepsy and oncology-driven expansion.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Neutral.
The score is driven primarily by strong cash flow and improved leverage, supported by a generally constructive earnings-call outlook (notably zanidatamab data and durable core product performance). These positives are moderated by the 2025 GAAP loss (hurting valuation via a negative P/E) and technically overbought conditions that increase near-term volatility risk.
To see Spark’s full report on JAZZ stock, click here.
More about Jazz Pharmaceuticals
YTD Price Performance: 7.06%
Average Trading Volume: 1,048,032
Technical Sentiment Signal: Buy
Current Market Cap: $11.2B